What medication is recommended to lower elevated triglyceride levels?

Medication to Lower Triglycerides

For patients with triglycerides 150-499 mg/dL and established cardiovascular disease or high risk, statins are first-line therapy, with icosapent ethyl (purified EPA) as the only evidence-based add-on therapy that reduces cardiovascular mortality; for severe hypertriglyceridemia ≥500 mg/dL, fibrates are the drugs of choice to prevent pancreatitis. 1, 2, 3

Moderate Hypertriglyceridemia (150-499 mg/dL)

Primary Therapy: Statins

• Statins should be initiated first in patients with moderate hypertriglyceridemia who have ASCVD or are at increased cardiovascular risk, as they reduce both LDL-C and triglycerides by 10-30% while providing proven cardiovascular benefit 2, 4
• High-dose statins (atorvastatin 80 mg or rosuvastatin 40 mg) can lower triglycerides by 25-30% 2
• Statins address the underlying atherogenic lipoprotein burden (apolipoprotein B) that drives cardiovascular risk, not just triglyceride levels 5, 6

Add-On Therapy: Icosapent Ethyl

• For patients with persistent triglycerides 150-499 mg/dL despite statin therapy and established ASCVD or diabetes with additional risk factors, icosapent ethyl (purified EPA) 4 grams daily is the only add-on therapy with proven cardiovascular mortality benefit (NNT=111 to prevent one cardiovascular death over 5 years) 1, 7, 8
• The 2025 AACE guideline conditionally suggests EPA (icosapent ethyl) in addition to statins for this population, though patients should be informed of small increased risks of atrial fibrillation and major bleeding 1

Therapies NOT Recommended

• Combined EPA+DHA (standard fish oil) should NOT be used as add-on to statin therapy, as it provides no clinically meaningful cardiovascular benefit 1
• Niacin is strongly recommended AGAINST in combination with statins due to trivial benefits and increased risks of infection, bleeding, and hyperglycemic events requiring hospitalization 1
• Fibrates may be considered but lack strong outcome data in this triglyceride range when added to statins 1, 5

Severe Hypertriglyceridemia (≥500 mg/dL)

Immediate Management Priority

• The primary goal is preventing acute pancreatitis, not cardiovascular risk reduction 2, 9, 3
• Implement very-low-fat diet (10-15% of calories, or <5% if triglycerides ≥1,000 mg/dL) immediately 3, 7
• Eliminate alcohol completely and severely restrict added sugars 9, 3
• Identify and treat secondary causes: optimize glycemic control with insulin if needed, discontinue estrogen therapy, address hypothyroidism 2, 9, 3

Pharmacotherapy: Fibrates First-Line

• Fibrates are the drugs of choice for severe hypertriglyceridemia, lowering triglycerides by 30-50% 2, 9, 2, 4
• Gemfibrozil 600 mg twice daily or fenofibrate 54-160 mg daily 10, 2
• Fibrates should be started before or instead of statins when triglycerides are ≥500 mg/dL to prevent pancreatitis 11, 12, 13

Additional Triglyceride-Lowering Options

• Prescription omega-3 fatty acids (EPA or EPA+DHA) at 3-4 grams daily can lower triglycerides by 20-50% and may be added to fibrates 2, 3, 4
• Niacin (immediate-release) 2-4 grams daily lowers triglycerides by 20-50% but use with caution in diabetes due to worsening glycemic control 2, 4

When Triglycerides Reach <500 mg/dL

• After triglycerides are reduced below 500 mg/dL with fibrate therapy, add statin therapy to address LDL-C and cardiovascular risk 12, 13, 3
• Target non-HDL-C <130 mg/dL if possible 11, 12, 13

Critical Combination Therapy Warnings

• Avoid gemfibrozil + statin combinations due to significantly increased myopathy risk; fenofibrate is safer if combination is necessary 14, 9
• When combining fibrate with statin, use lower statin doses, take fibrate in morning and statin in evening, and monitor for myalgia 9, 12
• Risk of myopathy increases with renal disease, advanced age, and polypharmacy 2

Insufficient Evidence Situations

• There is insufficient evidence to recommend for or against EPA, EPA+DHA, or niacin specifically in patients with severe hypertriglyceridemia ≥500 mg/dL, as these patients were excluded from major trials 1
• No trials have reported effects of these agents on pancreatitis prevention 1
• Clinical judgment must guide therapy in severe cases, prioritizing pancreatitis prevention with fibrates and lifestyle modification 2, 3